Johnson & Johnson EBIT

As of the most recent data (September 2026), JNJ.TO shows a EBIT of $23B. That compares with $32B in the prior-year period — down 29.7% year over year. That is below the Healthcare sector average of $130B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, JNJ.TO's EBIT is now $23B (was $32B) — a 29.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Johnson & Johnson is outperforming or lagging.

The Healthcare sector average EBIT is about $130B. Johnson & Johnson is at $23B, which is lower that average. That is roughly 83.2% below the sector mean. Use the comparison chart on this page to see how JNJ.TO stacks up against individual peers as well.

Tracking JNJ.TO's ebit over time shows whether Johnson & Johnson is scaling, shrinking, or reshaping that part of the business. The current reading is $23B That compares with $32B in the prior-year period — down 29.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Johnson & Johnson's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $23B) with ownership activity and broader fundamentals.